Mefuparib Hydrochloride Polymorph Control for Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for preparing 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride (Mefuparib hydrochloride) do not account for different crystal forms, which can affect its dissolution, pharmacokinetics, and bioavailability, thereby impacting the drug's efficacy and safety.
Innovation Solution
The invention provides three distinct polymorphs (crystal forms A, B, and C) of Mefuparib hydrochloride, along with characterization methods and a preparation process involving solvent selection and pH adjustment, enabling large-scale production of high-purity crystals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If different crystal forms of Mefuparib hydrochloride are used, then dissolution rate and bioavailability are improved, but manufacturing complexity increases due to the need to control and identify specific polymorphs
Solution Approach 1:
The patent applies parameter changes by systematically varying crystallization conditions including solvent types (ethanol, methanol, acetonitrile, etc.), temperatures (0°C to 80°C), pH values (adjusted with HCl), and evaporation rates to obtain different polymorphs. This allows control over crystal form while maintaining manageable process complexity through documented parameter-crystal form relationships
Solution Approach 2:
The patent utilizes phase transitions during crystallization processes, including cooling crystallization (80°C to room temperature or 0°C), evaporation crystallization (concentrating solutions to induce precipitation), and pH-induced phase separation. These controlled phase transitions enable reliable formation of specific polymorphs with desired properties
2Reliability
If polymorph characterization and control methods are implemented, then drug efficacy and safety are improved, but production time and process steps increase
Solution Approach 1:
The patent employs preliminary action by pre-establishing the relationship between crystallization parameters and resulting polymorph forms. By documenting which solvent-temperature-pH combinations yield which crystal forms, the process allows direct preparation of desired polymorphs without extensive trial-and-error during production, reducing overall development and production time
Solution Approach 2:
The patent replaces complex mechanical characterization systems with simpler analytical methods. Instead of requiring sophisticated in-situ monitoring equipment, the invention uses standard analytical techniques (XRD, DSC, HPLC) to confirm polymorph formation, significantly reducing equipment complexity and analysis time while maintaining reliable quality control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polymorphs exhibit high crystallinity and thermal stability, facilitating easy storage and effective pharmaceutical compositions for treating diseases related to PARP, including tumors and inflammation.
Implementation Method 1
the powder diffraction pattern of crystal form A is as follows... crystal form B is as follows... crystal form C is as follows
Implementation Method 2
the powder diffraction pattern of crystal form A is as follows: 2θ angle / ° d / A intensity%
Data Source
Figure 1a~1b
Figure 1c~1d
Figure 1e~2a
AI summary
Disclosed are a 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, a preparation method therefor and an application thereof. Specifically, disclosed are three crystalline forms, i.e., crystalline forms A, B, and C, of 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride (formula I), preparation methods for the three crystalline forms, and use of the three crystalline forms in preparation of drugs. (I)